Hilltop Holdings’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Hilltop Holdings’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,720	Closed	-$46K	–	484
2017 Q4	$46K	Buy	+10,720	New	+$51.1K	0.01%	328
2017 Q3	–	Sell	-10,720	Closed	-$16K	–	339
2017 Q2	$16K	Hold	10,720	–	–	﹤0.01%	311
2017 Q1	$28K	Hold	10,720	–	–	0.01%	319
2016 Q4	$27K	Hold	10,720	–	–	0.01%	316
2016 Q3	$33K	Hold	10,720	–	–	0.01%	306
2016 Q2	$34K	Hold	10,720	–	–	0.01%	293
2016 Q1	$33K	Hold	10,720	–	–	0.01%	294
2015 Q4	$43K	Hold	10,720	–	–	0.01%	318
2015 Q3	$49K	Buy	+10,720	New	+$56.1K	0.01%	323
2015 Q2	–	Sell	-10,720	Closed	-$67K	–	360
2015 Q1	$67K	Buy	+10,720	New	+$61.9K	0.02%	327

Other funds holding ECYT

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Hilltop Holdings's ECYT Position: Q1 2018 in Review

Hilltop Holdings sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 10,720 shares — an estimated $46K sold.

Hilltop Holdings first reported a position in ECYT in Q1 2015 and held it in 10 quarters. The position peaked at $67K in Q1 2015. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

Hilltop Holdings reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Hilltop Holdings sold 10,720 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $46K.
Hilltop Holdings first reported a position in Endocyte, Inc. Common Stock in Q1 2015 and held it in 10 quarters.
Hilltop Holdings's Endocyte, Inc. Common Stock position peaked at $67K in Q1 2015.
89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Hilltop Holdings's 13F filing for Q1 2018, filed 15 May 2018.